Skip to content

Enterprise value at other companies

McKesson logo
McKessonMCK
$104.3B+19.6%
Evolent Health, Inc. logo
Evolent Health, Inc.EVH
$1.1B-36.5%
Immunome logo
ImmunomeIMNM
$1.9B+470%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$5.3B-22.3%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$14.71B+3.4%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$10B+71.5%

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Calculated from The Oncology Institute, Inc.’s reported figures.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s enterprise value?
The Oncology Institute, Inc. (TOI) reported enterprise value of $378.11M in Q1 2026.
How has The Oncology Institute, Inc.'s enterprise value changed year-over-year?
The Oncology Institute, Inc.'s enterprise value increased by 132.3% year-over-year, from $162.74M to $378.11M.
What is the long-term trend for The Oncology Institute, Inc.'s enterprise value?
Over 5 years (2020 to 2025), The Oncology Institute, Inc.'s enterprise value has grown at a -10.3% compound annual growth rate (CAGR), from $724.05M to $420.42M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.